Department of Cardiovascular Surgery, Xinqiao Hospital, Army Medical University, Chongqing, 400037, China.
Southwest Hospital, Army Medical University, Chongqing, 400038, China.
Curr Med Sci. 2018 Dec;38(6):1075-1080. doi: 10.1007/s11596-018-1986-y. Epub 2018 Dec 7.
The purpose of this study was to analyze the components of inpatient costs for coronary artery bypass graft (CABG) according to preoperative risk stratification and to provide evidence for improvement of diagnosis-related groups (DRGs) payment. All patients (n=458) receiving an isolated CABG between January 2014 and December 2016 in a tertiary referral center, in southwest China, were analyzed. Hospital mortality was predicted by the EuroSCORE II for each patient. The patients were subdivided into two groups according to the observed mortality (1.97%, 9/458): a high-risk group (group H, predicted mortality ≥1.97%) and a low-risk group (group L, predicted mortality <1.97%). Clinical outcomes, resource use, in-hospital direct costs, and reimbursement expenses were compared between the two groups. Significant differences existed between group L and group H in postoperative mortality (0.4% vs. 3.4%; P=0.02), postoperative complications (10.6% vs. 45.7%; P<0.001), postoperative length of hospital stay (17.5±4.9 days vs. 18.8±6.5 days, P=0.01), in-hospital costs ($20 256±3096 vs. $23 334±6332; P<0.001), and reimbursement expenses ($7775±2627 vs. $9639±3917; P<0.001). In general, a higher EuroSCORE II was significantly associated with a worse clinical outcome and increased costs. The CABG cost data provide evidence for improvement of DRGs payment.
本研究旨在根据术前风险分层分析冠状动脉旁路移植术(CABG)的住院费用构成,并为改进诊断相关分组(DRGs)支付提供证据。对 2014 年 1 月至 2016 年 12 月在中国西南部一家三级转诊中心接受单纯 CABG 的 458 例患者进行分析。每位患者的医院死亡率均采用 EuroSCORE II 进行预测。根据观察到的死亡率(1.97%,9/458)将患者分为两组:高危组(组 H,预测死亡率≥1.97%)和低危组(组 L,预测死亡率<1.97%)。比较两组患者的临床结局、资源利用、住院直接费用和报销费用。组 H 与组 L 在术后死亡率(0.4%比 3.4%;P=0.02)、术后并发症(10.6%比 45.7%;P<0.001)、术后住院时间(17.5±4.9 天比 18.8±6.5 天,P=0.01)、住院费用(20256±3096 美元比 23334±6332 美元,P<0.001)和报销费用(7775±2627 美元比 9639±3917 美元,P<0.001)方面存在显著差异。总体而言,EuroSCORE II 越高,临床结局越差,费用越高。CABG 成本数据为改进 DRGs 支付提供了证据。